^
    1d
    Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention (clinicaltrials.gov)
    P1, N=0, Withdrawn, Northwell Health | N=24 --> 0 | Trial completion date: Sep 2025 --> Mar 2026 | Recruiting --> Withdrawn
    Enrollment change • Trial completion date • Trial withdrawal
    |
    minocycline
    13d
    Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (clinicaltrials.gov)
    P4, N=480, Completed, Shanghai Jiao Tong University School of Medicine | Recruiting --> Completed | Trial completion date: Aug 2026 --> Feb 2026 | Trial primary completion date: Aug 2026 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    minocycline
    28d
    Topical Minocycline for CARP (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, Medical University of South Carolina
    New P1 trial
    |
    minocycline
    1m
    Memocycline: Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories (clinicaltrials.gov)
    P=N/A, N=138, Completed, Psychiatric University Hospital, Zurich | Active, not recruiting --> Completed | N=210 --> 138 | Trial primary completion date: Nov 2025 --> Mar 2026
    Trial completion • Enrollment change • Trial primary completion date
    |
    minocycline
    1m
    A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (clinicaltrials.gov)
    P1/2, N=33, Recruiting, TenNor Therapeutics Inc. | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Aug 2026 | Completed --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date
    |
    minocycline
    1m
    A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (clinicaltrials.gov)
    P1/2, N=9, Completed, TenNor Therapeutics Inc. | Recruiting --> Completed | N=33 --> 9 | Trial completion date: Aug 2026 --> Jan 2026 | Trial primary completion date: Aug 2026 --> Jan 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    minocycline
    2ms
    Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics (clinicaltrials.gov)
    P1, N=42, Recruiting, Case Western Reserve University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    minocycline
    2ms
    Fecal Molecular Susceptibility-guided Hp Rescue Therapy (clinicaltrials.gov)
    P4, N=290, Not yet recruiting, Shanghai Zhongshan Hospital
    New P4 trial • HEOR
    |
    minocycline
    2ms
    Fecal Molecular Susceptibility-guided Hp First-line Therapy (clinicaltrials.gov)
    P4, N=544, Not yet recruiting, Shanghai Zhongshan Hospital
    New P4 trial • HEOR
    |
    minocycline
    2ms
    Microglia alter autonomic nuclei neuronal activation after peripheral cytokine challenge. (PubMed, Am J Physiol Cell Physiol)
    When animals were challenged with TNFα after receiving minocycline, fewer c-Fos-positive cells were induced in the DVC and selectively in the rostral VLM. These findings highlight the spatial selectivity of cells in the brainstem to increased peripheral pro-inflammatory signaling, as well as the impact of resident microglia on autonomic circuitry responses.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
    |
    minocycline
    2ms
    Endothelial oncogenic KRAS mutation drives the dynamics of microglia and macrophages in brain arteriovenous malformation. (PubMed, JCI Insight)
    Inhibition of MG/Mϕ with long-term minocycline treatment attenuated the incidence of ICHs around bAVMs. Our study indicates that MG/Mϕ are involved in destabilization of KRAS-induced bAVM, leading to hemorrhagic conversion/ICH. Thus, modulation of MG/Mϕ may reduce ICH risk in bAVM patients.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CCR2 (C-C Motif Chemokine Receptor 2) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    |
    KRAS mutation • KRAS G12
    |
    minocycline
    2ms
    Efficacy and Safety of Keverprazan-Minocycline Dual Therapy Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter pylori Infection: A Prospective Multicenter Randomized Controlled Trial (ChiCTR2600116736)
    P=N/A, N=340, Not yet recruiting, Northern Jiangsu People's Hospital; Northern Jiangsu People's Hospital
    New trial
    |
    minocycline